Nilotinib
Sign in to save this workspacePrimary targets: BCR_ABL, ABL1, ABL2_ARG · FDA status: FDA Approved
Selectivity scorecard
KISS
96.49
Gini
0.765
CATDS
0.020
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Nilotinib. Strongest target: DDR2 at 99.7% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | DDR2 | 99.7% | 0.3% |
| 2 | EPHB1 | 98.8% | 1.2% |
| 3 | EPHB2 | 98.7% | 1.3% |
| 4 | DDR1 | 98.5% | 1.5% |
| 5 | RAF1 | 98.3% | 1.7% |
| 6 | ABL1 | 98.0% | 2.0% |
| 7 | PDGFRA | 97.9% | 2.1% |
| 8 | EPHA2 | 97.6% | 2.4% |
| 9 | ABL2_ARG | 96.9% | 3.1% |
| 10 | LCK | 95.1% | 4.9% |
| 11 | EPHB4 | 94.6% | 5.4% |
| 12 | EPHA4 | 94.4% | 5.6% |
| 13 | EPHA5 | 93.8% | 6.2% |
| 14 | FMS | 91.4% | 8.6% |
| 15 | EPHB3 | 89.9% | 10.1% |
| 16 | ZAK_MLTK | 87.8% | 12.2% |
| 17 | PDGFRB | 86.7% | 13.3% |
| 18 | BRAF | 85.8% | 14.2% |
| 19 | P38B_MAPK11 | 83.9% | 16.1% |
| 20 | ARAF | 81.8% | 18.2% |
Selectivity landscape
Where Nilotinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Nilotinib.
Atlas insights for Nilotinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 2085.73 | |
| ALLOGRAFT_REJECTION | 6030.73 | |
| ANDROGEN_RESPONSE | 751.26 | |
| ANGIOGENESIS | 1235.38 | |
| APICAL_JUNCTION | 7203.42 | |
| APICAL_SURFACE | 626.48 | |
| APOPTOSIS | 5251.31 | |
| BILE_ACID_METABOLISM | 600.59 | |
| CHOLESTEROL_HOMEOSTASIS | 1179.18 | |
| COAGULATION | 1008.57 | |
| COMPLEMENT | 4202.48 | |
| DNA_REPAIR | 1109.37 | |
| E2F_TARGETS | 2993.73 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 1352.27 | |
| ESTROGEN_RESPONSE_EARLY | 2274.16 | |
| ESTROGEN_RESPONSE_LATE | 1783.06 | |
| FATTY_ACID_METABOLISM | 505.12 | |
| G2M_CHECKPOINT | 3406.10 | |
| GLYCOLYSIS | 1795.17 | |
| HEDGEHOG_SIGNALING | 772.11 | |
| HEME_METABOLISM | 1458.31 | |
| HYPOXIA | 3114.78 | |
| IL2_STAT5_SIGNALING | 2401.81 | |
| IL6_JAK_STAT3_SIGNALING | 3286.96 | |
| INFLAMMATORY_RESPONSE | 3610.42 | |
| INTERFERON_ALPHA_RESPONSE | 741.63 | |
| INTERFERON_GAMMA_RESPONSE | 3971.57 | |
| KRAS_SIGNALING_DN | 620.68 | |
| KRAS_SIGNALING_UP | 2501.34 | |
| MITOTIC_SPINDLE | 5108.69 | |
| MTORC1_SIGNALING | 2367.21 | |
| MYC_TARGETS_V1 | 2587.59 | |
| MYC_TARGETS_V2 | 552.91 | |
| MYOGENESIS | 1948.63 | |
| NOTCH_SIGNALING | 149.68 | |
| OXIDATIVE_PHOSPHORYLATION | 880.77 | |
| P53_PATHWAY | 2684.70 | |
| PANCREAS_BETA_CELLS | 213.98 | |
| PEROXISOME | 770.66 | |
| PI3K_AKT_MTOR_SIGNALING | 6233.27 | |
| PROTEIN_SECRETION | 1266.14 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 484.11 | |
| SPERMATOGENESIS | 1081.80 | |
| TGF_BETA_SIGNALING | 1285.79 | |
| TNFA_SIGNALING_VIA_NFKB | 3235.02 | |
| UNFOLDED_PROTEIN_RESPONSE | 708.40 | |
| UV_RESPONSE_DN | 3681.37 | |
| UV_RESPONSE_UP | 2576.98 | |
| WNT_BETA_CATENIN_SIGNALING | 1159.54 | |
| XENOBIOTIC_METABOLISM | 1129.89 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.830 |
| SRR23303752 | — | 0.829 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.816 |
| aMVAC.P_005_TURBT_S223 | — | 0.813 |
| C3N-03420 | — | 0.811 |
Annotations
Sign in to read and post annotations.
Loading…